176 related articles for article (PubMed ID: 38755688)
1. RECOVER-NEURO: study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC).
Knopman DS; Laskowitz DT; Koltai DC; Charvet LE; Becker JH; Federman AD; Wisnivesky J; Mahncke H; Van Vleet TM; Bateman L; Kim DY; O'Steen A; James M; Silverstein A; Lokhnygina Y; Rich J; Feger BJ; Zimmerman KO
Trials; 2024 May; 25(1):326. PubMed ID: 38755688
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC).
Santana K; França E; Sato J; Silva A; Queiroz M; de Farias J; Rodrigues D; Souza I; Ribeiro V; Caparelli-Dáquer E; Teixeira AL; Charvet L; Datta A; Bikson M; Andrade S
Brain Stimul; 2023; 16(1):100-107. PubMed ID: 36693536
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial testing the efficacy of Fit after COVID, a cognitive behavioural therapy targeting severe post-infectious fatigue following COVID-19 (ReCOVer): study protocol.
Kuut TA; Müller F; Aldenkamp A; Assmann-Schuilwerve E; Braamse A; Geerlings SE; Gibney KB; Kanaan RAA; Nieuwkerk P; Olde Hartman TC; Pauëlsen D; Prins M; Slieker K; Van Vugt M; Bleeker-Rovers CP; Keijmel SP; Knoop H
Trials; 2021 Dec; 22(1):867. PubMed ID: 34857010
[TBL] [Abstract][Full Text] [Related]
4. Improving cognition in severe mental illness by combining cognitive remediation and transcranial direct current stimulation: study protocol for a pragmatic randomized controlled pilot trial (HEADDSET).
Poppe A; Bais L; van Duin D; Ćurčić-Blake B; Pijnenborg GHM; van der Meer L
Trials; 2021 Apr; 22(1):275. PubMed ID: 33849658
[TBL] [Abstract][Full Text] [Related]
5. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
[TBL] [Abstract][Full Text] [Related]
6. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
[TBL] [Abstract][Full Text] [Related]
7. Plasma proteomics show altered inflammatory and mitochondrial proteins in patients with neurologic symptoms of post-acute sequelae of SARS-CoV-2 infection.
Hanson BA; Visvabharathy L; Orban ZS; Jimenez M; Batra A; Liotta EM; DeLisle RK; Klausner JD; Cohen P; Padhye AS; Tachas G; Koralnik IJ
Brain Behav Immun; 2023 Nov; 114():462-474. PubMed ID: 37704012
[TBL] [Abstract][Full Text] [Related]
8. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.
Horwitz LI; Thaweethai T; Brosnahan SB; Cicek MS; Fitzgerald ML; Goldman JD; Hess R; Hodder SL; Jacoby VL; Jordan MR; Krishnan JA; Laiyemo AO; Metz TD; Nichols L; Patzer RE; Sekar A; Singer NG; Stiles LE; Taylor BS; Ahmed S; Algren HA; Anglin K; Aponte-Soto L; Ashktorab H; Bassett IV; Bedi B; Bhadelia N; Bime C; Bind MC; Black LJ; Blomkalns AL; Brim H; Castro M; Chan J; Charney AW; Chen BK; Chen LQ; Chen P; Chestek D; Chibnik LB; Chow DC; Chu HY; Clifton RG; Collins S; Costantine MM; Cribbs SK; Deeks SG; Dickinson JD; Donohue SE; Durstenfeld MS; Emery IF; Erlandson KM; Facelli JC; Farah-Abraham R; Finn AV; Fischer MS; Flaherman VJ; Fleurimont J; Fonseca V; Gallagher EJ; Gander JC; Gennaro ML; Gibson KS; Go M; Goodman SN; Granger JP; Greenway FL; Hafner JW; Han JE; Harkins MS; Hauser KSP; Heath JR; Hernandez CR; Ho O; Hoffman MK; Hoover SE; Horowitz CR; Hsu H; Hsue PY; Hughes BL; Jagannathan P; James JA; John J; Jolley S; Judd SE; Juskowich JJ; Kanjilal DG; Karlson EW; Katz SD; Kelly JD; Kelly SW; Kim AY; Kirwan JP; Knox KS; Kumar A; Lamendola-Essel MF; Lanca M; Lee-Lannotti JK; Lefebvre RC; Levy BD; Lin JY; Logarbo BP; Logue JK; Longo MT; Luciano CA; Lutrick K; Malakooti SK; Mallett G; Maranga G; Marathe JG; Marconi VC; Marshall GD; Martin CF; Martin JN; May HT; McComsey GA; McDonald D; Mendez-Figueroa H; Miele L; Mittleman MA; Mohandas S; Mouchati C; Mullington JM; Nadkarni GN; Nahin ER; Neuman RB; Newman LT; Nguyen A; Nikolich JZ; Ofotokun I; Ogbogu PU; Palatnik A; Palomares KTS; Parimon T; Parry S; Parthasarathy S; Patterson TF; Pearman A; Peluso MJ; Pemu P; Pettker CM; Plunkett BA; Pogreba-Brown K; Poppas A; Porterfield JZ; Quigley JG; Quinn DK; Raissy H; Rebello CJ; Reddy UM; Reece R; Reeder HT; Rischard FP; Rosas JM; Rosen CJ; Rouphael NG; Rouse DJ; Ruff AM; Saint Jean C; Sandoval GJ; Santana JL; Schlater SM; Sciurba FC; Selvaggi C; Seshadri S; Sesso HD; Shah DP; Shemesh E; Sherif ZA; Shinnick DJ; Simhan HN; Singh U; Sowles A; Subbian V; Sun J; Suthar MS; Teunis LJ; Thorp JM; Ticotsky A; Tita ATN; Tragus R; Tuttle KR; Urdaneta AE; Utz PJ; VanWagoner TM; Vasey A; Vernon SD; Vidal C; Walker T; Ward HD; Warren DE; Weeks RM; Weiner SJ; Weyer JC; Wheeler JL; Whiteheart SW; Wiley Z; Williams NJ; Wisnivesky JP; Wood JC; Yee LM; Young NM; Zisis SN; Foulkes AS
PLoS One; 2023; 18(6):e0286297. PubMed ID: 37352211
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.
Moghimi N; Di Napoli M; Biller J; Siegler JE; Shekhar R; McCullough LD; Harkins MS; Hong E; Alaouieh DA; Mansueto G; Divani AA
Curr Neurol Neurosci Rep; 2021 Jun; 21(9):44. PubMed ID: 34181102
[TBL] [Abstract][Full Text] [Related]
11. Self-managing symptoms of Long COVID: an education and strategies research protocol.
Rybkina J; Jacob N; Colella B; Gold D; Stewart DE; Ruttan LA; Meusel LC; McAndrews MP; Abbey S; Green R
Front Public Health; 2024; 12():1106578. PubMed ID: 38384879
[TBL] [Abstract][Full Text] [Related]
12. Neuromodulation through brain stimulation-assisted cognitive training in patients with post-COVID-19 cognitive impairment (Neuromod-COV): study protocol for a PROBE phase IIb trial.
Thams F; Antonenko D; Fleischmann R; Meinzer M; Grittner U; Schmidt S; Brakemeier EL; Steinmetz A; Flöel A
BMJ Open; 2022 Apr; 12(4):e055038. PubMed ID: 35410927
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and auditory biomarker analysis of fronto-temporal transcranial direct current stimulation (tDCS) in targeting cognitive impairment associated with recent-onset schizophrenia: study protocol for a multicenter randomized double-blind sham-controlled trial.
Dondé C; Bastin J; Pouchon A; Costes N; Fakra E; Galvão F; Gay A; Haesebaert F; Lamalle L; Mérida I; Rigon M; Schneider F; Troprès I; Brunelin J; Polosan M
Trials; 2023 Feb; 24(1):141. PubMed ID: 36829240
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
[TBL] [Abstract][Full Text] [Related]
15. Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection.
Hanson BA; Visvabharathy L; Ali ST; Kang AK; Patel TR; Clark JR; Lim PH; Orban ZS; Hwang SS; Mattoon D; Batra A; Liotta EM; Koralnik IJ
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35256481
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
17. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
